Alzheimer's breakthrough: Scientists create first twice-a-day tablet that can repair damage and restore brain function to that of a healthy person in just NINE MONTHS
2 posters
Page 1 of 1
Alzheimer's breakthrough: Scientists create first twice-a-day tablet that can repair damage and restore brain function to that of a healthy person in just NINE MONTHS
A breakthrough Alzheimer's drug edges scientists one step closer to a cure, new research suggests.
Taken twice a day, a tablet, known as LMTX, significantly improves dementia sufferers' brain injuries to the extent their MRI scans resemble those of healthy people after just nine months, a study found.
Lead author Professor Gordon Wilcock from the University of Oxford told MailOnline: 'I haven't seen such brain injury recovery before after a drug treatment.'
LMTX, which is under investigation, also significantly improves patients' abilities to carry out everyday tasks such as bathing and dressing themselves, while also boosting their capabilities to correctly name objects and remember the date, the research adds.
The drug contains a chemical that dissolves protein 'tangles' in the brain that clump together to form plaques in the region associated with memory, according to its manufacturer TauRx Pharmaceuticals.
Dissolving these tangles and preventing the formation of new plaques may slow or even halt memory loss in dementia sufferers, the pharma company adds.
Alzheimer's disease affects around 850,000 people in the UK and 5.5 million in the US.
Researchers from the universities of Oxford and Aberdeen analysed 800 Alzheimer's patients across 12 countries.
The study's participants received a 100mg LMTX tablet twice a day for 18 months.
They were tested on their ability to name objects, follow commands such as 'make a fist', recall items from a list of 10 and identify their name, the time of day and date.
Their ability to eat without help, use a telephone, wash and dress themselves, and control their bowel and bladder was also assessed.
MRI scans monitored the participants' brain injury.
Results reveal after just nine months patients' brain injuries improved significantly to the extent their MRI scans resembled those of healthy, elderly people without dementia.
Professor Wilcock said: 'I haven't seen such brain injury recovery before after a drug treatment.'
The participants' ability to complete tasks such as correctly naming objects and eating unassisted also significantly improved.
Drug side effects were largely gastrointestinal or urinary related, which caused 40 patients to discontinue the treatment.
Professor Wilcock said: 'This drug, like all drugs, has side effects, the bigger the dose the more likely you are to get side effects.'
Further studies investigating a lower LMTX dose are due to begin shortly.
Professor Wilcock said: 'It will only be approved and available for patients if future trials are positive. It will probably be another five years.'
The findings were published in the Journal of Alzheimer's Disease.
Dr James Pickett, head of research at Alzheimer's Society, said: 'When the results of the LMTX drug were first presented in 2016, questions were raised amongst the research community about how the results were interpreted.
'This newer trial takes a different analytical approach and while we encourage researchers to explore all potential angles in their data there are some issues remaining that mean we cannot interpret this data as a positive result.
'These issues include the lack of a strong control group and that the numbers of people who were taking LMTX alone are quite small.
'We have been waiting more than 15 years for a new drug for dementia. This was the first large-scale trial to target another potential culprit, the tau protein. From the results that we have seen, we cannot say that LMTX is an effective drug for Alzheimer's.
'However we look forward to seeing other innovative approaches to drug development in dementia - including targeting treatments at more than just the amyloid protein.'
Dr Hilda Hayo, CEO and chief admiral nurse at Dementia UK, said: 'Dementia UK welcomes anything that might lead to successful treatment of dementia and other neurological conditions.
'We are interested in seeing further results which come from this study, which could eventually lead to a cure for dementia.'
http://www.dailymail.co.uk/health/article-5128431/Alzheimers-drug-edges-scientists-closer-cure.html
Taken twice a day, a tablet, known as LMTX, significantly improves dementia sufferers' brain injuries to the extent their MRI scans resemble those of healthy people after just nine months, a study found.
Lead author Professor Gordon Wilcock from the University of Oxford told MailOnline: 'I haven't seen such brain injury recovery before after a drug treatment.'
LMTX, which is under investigation, also significantly improves patients' abilities to carry out everyday tasks such as bathing and dressing themselves, while also boosting their capabilities to correctly name objects and remember the date, the research adds.
The drug contains a chemical that dissolves protein 'tangles' in the brain that clump together to form plaques in the region associated with memory, according to its manufacturer TauRx Pharmaceuticals.
Dissolving these tangles and preventing the formation of new plaques may slow or even halt memory loss in dementia sufferers, the pharma company adds.
Alzheimer's disease affects around 850,000 people in the UK and 5.5 million in the US.
Researchers from the universities of Oxford and Aberdeen analysed 800 Alzheimer's patients across 12 countries.
The study's participants received a 100mg LMTX tablet twice a day for 18 months.
They were tested on their ability to name objects, follow commands such as 'make a fist', recall items from a list of 10 and identify their name, the time of day and date.
Their ability to eat without help, use a telephone, wash and dress themselves, and control their bowel and bladder was also assessed.
MRI scans monitored the participants' brain injury.
Results reveal after just nine months patients' brain injuries improved significantly to the extent their MRI scans resembled those of healthy, elderly people without dementia.
Professor Wilcock said: 'I haven't seen such brain injury recovery before after a drug treatment.'
The participants' ability to complete tasks such as correctly naming objects and eating unassisted also significantly improved.
Drug side effects were largely gastrointestinal or urinary related, which caused 40 patients to discontinue the treatment.
Professor Wilcock said: 'This drug, like all drugs, has side effects, the bigger the dose the more likely you are to get side effects.'
Further studies investigating a lower LMTX dose are due to begin shortly.
Professor Wilcock said: 'It will only be approved and available for patients if future trials are positive. It will probably be another five years.'
The findings were published in the Journal of Alzheimer's Disease.
Dr James Pickett, head of research at Alzheimer's Society, said: 'When the results of the LMTX drug were first presented in 2016, questions were raised amongst the research community about how the results were interpreted.
'This newer trial takes a different analytical approach and while we encourage researchers to explore all potential angles in their data there are some issues remaining that mean we cannot interpret this data as a positive result.
'These issues include the lack of a strong control group and that the numbers of people who were taking LMTX alone are quite small.
'We have been waiting more than 15 years for a new drug for dementia. This was the first large-scale trial to target another potential culprit, the tau protein. From the results that we have seen, we cannot say that LMTX is an effective drug for Alzheimer's.
'However we look forward to seeing other innovative approaches to drug development in dementia - including targeting treatments at more than just the amyloid protein.'
Dr Hilda Hayo, CEO and chief admiral nurse at Dementia UK, said: 'Dementia UK welcomes anything that might lead to successful treatment of dementia and other neurological conditions.
'We are interested in seeing further results which come from this study, which could eventually lead to a cure for dementia.'
http://www.dailymail.co.uk/health/article-5128431/Alzheimers-drug-edges-scientists-closer-cure.html
HoratioTarr- Forum Detective ????♀️
- Posts : 10037
Join date : 2014-01-12
Re: Alzheimer's breakthrough: Scientists create first twice-a-day tablet that can repair damage and restore brain function to that of a healthy person in just NINE MONTHS
That,s great but it takes years for new drugs to come on line doesn't it?
nicko- Forum Detective ????♀️
- Posts : 13368
Join date : 2013-12-07
Age : 83
Location : rainbow bridge
Similar topics
» Hours After Pigs’ Death, Scientists Restore Brain Cell Activity
» In Latest Breakthrough, Scientists Successfully Regrow Brain Tissue That Was Damaged by a Stroke
» The brain patterns of human consciousness: Scientists discover signatures showing the mind is 'aware' in major breakthrough
» Scientists Could Tell Your Body To Repair Itself After A Heart Attack
» Poverty's most insidious damage is to a child's brain
» In Latest Breakthrough, Scientists Successfully Regrow Brain Tissue That Was Damaged by a Stroke
» The brain patterns of human consciousness: Scientists discover signatures showing the mind is 'aware' in major breakthrough
» Scientists Could Tell Your Body To Repair Itself After A Heart Attack
» Poverty's most insidious damage is to a child's brain
Page 1 of 1
Permissions in this forum:
You cannot reply to topics in this forum
Sat Mar 18, 2023 12:28 pm by Ben Reilly
» TOTAL MADNESS Great British Railway Journeys among shows flagged by counter terror scheme ‘for encouraging far-right sympathies
Wed Feb 22, 2023 5:14 pm by Tommy Monk
» Interesting COVID figures
Tue Feb 21, 2023 5:00 am by Tommy Monk
» HAPPY CHRISTMAS.
Sun Jan 01, 2023 7:33 pm by Tommy Monk
» The Fight Over Climate Change is Over (The Greenies Won!)
Thu Dec 15, 2022 3:59 pm by Tommy Monk
» Trump supporter murders wife, kills family dog, shoots daughter
Mon Dec 12, 2022 1:21 am by 'Wolfie
» Quill
Thu Oct 20, 2022 10:28 pm by Tommy Monk
» Algerian Woman under investigation for torture and murder of French girl, 12, whose body was found in plastic case in Paris
Thu Oct 20, 2022 10:04 pm by Tommy Monk
» Wind turbines cool down the Earth (edited with better video link)
Sun Oct 16, 2022 9:19 am by Ben Reilly
» Saying goodbye to our Queen.
Sun Sep 25, 2022 9:02 pm by Maddog
» PHEW.
Sat Sep 17, 2022 6:33 pm by Syl
» And here's some more enrichment...
Thu Sep 15, 2022 3:46 pm by Ben Reilly
» John F Kennedy Assassination
Thu Sep 15, 2022 3:40 pm by Ben Reilly
» Where is everyone lately...?
Thu Sep 15, 2022 3:33 pm by Ben Reilly
» London violence over the weekend...
Mon Sep 05, 2022 2:19 pm by Tommy Monk
» Why should anyone believe anything that Mo Farah says...!?
Wed Jul 13, 2022 1:44 am by Tommy Monk
» Liverpool Labour defends mayor role poll after turnout was only 3% and they say they will push ahead with the option that was least preferred!!!
Mon Jul 11, 2022 1:11 pm by Tommy Monk
» Labour leader Keir Stammer can't answer the simple question of whether a woman has a penis or not...
Mon Jul 11, 2022 3:58 am by Tommy Monk
» More evidence of remoaners still trying to overturn Brexit... and this is a conservative MP who should be drummed out of the party and out of parliament!
Sun Jul 10, 2022 10:50 pm by Tommy Monk
» R Kelly 30 years, Ghislaine Maxwell 20 years... but here in UK...
Fri Jul 08, 2022 5:31 pm by Original Quill